Vivaldi Biosciences enters into agreement with NIAID for LAIVs
Vivaldi will assist the NIAID, a subsidiary of the National Institutes of Health, in the creation of LAIVs against Influenza A H7N9. The H7N9 influenza strain poses a health threat because of its pandemic potential.
Vivaldi has a proprietary LAIV technology platform which utilizes the biology of the influenza nonstructural protein 1, one of the most harmful factors of the influenza virus. Vivaldi uses a novel approach in vaccine development which may provide wider range protection against infection.
Vivaldi also uses a proprietary technology in reverse genetics and plasmid rescue to alter the NS1 gene which produces replication-deficient LAIVs, causing a stronger immune response against the influenza virus.
"We are pleased that NIAID has taken an active interest in Vivaldi's NS1-based LAIV platform and reverse genetics technologies by collaborating with the company on this important program for pandemic preparedness," Vivaldi President and CEO Douglass B. Given said. "We look forward to working with Dr. Kanta Subbarao and her team at NIAID's Laboratory of Infectious Diseases. Promising activity and a favorable safety profile have been demonstrated in a Phase 1 study of our NS1-based LAIV for H5N1 influenza another strain with pandemic potential. This CRADA with NIAID supports our efforts to further develop the next generation of our LAIV technology with the H7N9 strain."
Vivaldi and NIAID research teams will work together towards the research and development of LAIVs. The program is expected to produce an Investigational New Drug which can potentially gain approval for a Phase 1 clinical trial.